Retatrutide

30/09/2026, 10:00

Health

Phase 3 Trials Point to Record Weight Loss with Triple-Hormone Drug

New Phase 3 trial data shows Eli Lilly’s retatrutide delivers up to 25 percent weight loss alongside improvements in sleep apnea and osteoarthritis.

About Us

Azat TV is a modern, independent media platform trusted for delivering timely, accurate, and unbiased news. From Armenia to the global stage, we are committed to providing fresh perspectives, in-depth reporting, and engaging stories that matter.

About Us | Editorial Policy & Standards | Privacy Policy

Our vision is to grow beyond a digital platform, becoming a leader in innovative media formats and fostering strong connections with our audience. With a focus on journalistic integrity and adaptability, Azat TV is dedicated to evolving alongside the needs of its viewers.

Azat TV: News Through a Different Lens. (Editorial opinions may differ.)

News Through a Different Lens

Search

Azat TV
Stay connected with Azat TV on social media! For inquiries or feedback, reach out to us through our pages or email us directly at info@azat.tv. We’d love to hear from you!

Bluesky
Facebook
Instagram
X
Pinterest
LinkedIn
Threads
YouTube

Retatrutide

Phase 3 Trials Point to Record Weight Loss with Triple-Hormone Drug